| HBcAb-positive | HBcAb-negative | P value | |
| Patients (no.) | 23 | 80 | |
| Gender (female, %) | 15 (65.2%) | 67 (83.8%) | >0.05 |
| Age (mean ± SD years) | 68.65 ± 7.37 | 63.32 ± 13.16 | <0.02 |
| Disease duration (years) | 10.08 ± 8.65 | 10.42 ± 9.72 | > 0.80 |
| Observation period (years) | 5.54 ± 4.28 | 5.92 ± 4.80 | >0.70 |
| Stage (I/II/III/IV) | 5/3/9/6 | 24/15/29/12 | |
| DAS28-CRP | 2.08 ± 0.73 | 2.12 ± 0.96 | >0.80 |
| RF positive | 17/23 (73.9%) | 55/80 (68.8%) | >0.50 |
| RF (U/ml) | 124.3 ± 203.4 | 127.9 ± 447.7 | >0.90 |
| ACPA positive | 21/23 (91.3%) | 58/80 (72.5%) | >0.05 |
| ACPA (U/ml) | 163.6 ± 104.2 | 124.1 ± 125.0 | >0.10 |
| Corticosteroids | 8/23 (34.8%) | 23/80 (28.8%) | >0.50 |
| MTX | 22/23 (95.6%) | 78/80 (97.5%) | >0.90 |
| AF | 0/23 | 7/80 (8.8%) | >0.30 |
| SASP | 4/23 (17.4%) | 16/80 (20.0%) | >0.50 |
| Buc | 4/23 (17.4%) | 8/80 (10.0%) | >0.80 |